Stay updated on Dupilumab in Chronic Urticaria Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Chronic Urticaria Clinical Trial page.

Latest updates to the Dupilumab in Chronic Urticaria Clinical Trial page
- CheckyesterdayChange DetectedMinor layout and formatting changes observed on the Study Details page, with no changes to core study data (status, enrollment, endpoints, eligibility). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

 - Check9 days agoNo Change Detected
 - Check30 days agoChange DetectedAdded a government funding status notice and updated the version to v3.2.0; removed the previous version tag v3.1.0.SummaryDifference4%

 - Check37 days agoChange DetectedAdded version tag v3.1.0 and removed several drug-safety topic sections; indicates content pruning in the drug-safety area with a version upgrade.SummaryDifference0.4%

 - Check52 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' link was removed (a minor UI change).SummaryDifference0.2%

 - Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.2%

 - Check66 days agoChange DetectedThe webpage has undergone significant updates, including the addition of specific facility names and locations in Germany, as well as new topics related to drug safety and skin conditions. Notably, the previous references to certain locations and topics have been removed.SummaryDifference4%

 
Stay in the know with updates to Dupilumab in Chronic Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Chronic Urticaria Clinical Trial page.